AGI-5198-抑制剂-深圳欣博盛生物科技有限公司

首页产品中心抑制剂

AGI-5198

品牌：Adipogen

官网链接

说明书

折扣/货期

货号：AG-CR1-3528-M005	规格：5 mg	目录价：￥960
货号：AG-CR1-3528-M025	规格：25 mg	目录价：￥2880

产品详情

* 以下信息仅供参考，详情请以原厂网站为准

产品名称:

AGI-5198

别名:

N-[2-(Cyclohexylamino)-1-(2-methylphenyl)-2-oxoethyl]-N-(3-fluorophenyl)-2-methyl-1H-imidazole-1-acetamide; IDH-C35

产品描述:

Potent and selective inhibitor of IDH1 (isocitrate dehydrogenase 1) R132H and R132C mutants in vitro with IC50 values of 0.07 and 0.16µM, respectively. Does not inhibit wild-type IDH1 or any of the examined IDH2 isoforms (IC50>100µM). Isocitrate dehydrogenases (IDHs) are nicotinamide adenine dinucleotide (NAD+) and NAD phosphate (NADP+)-dependent enzymes in the tricarboxylic acid (TCA) cycle that catalyze oxidative decarboxylation of isocitrate producing alpha-ketoglutarate (2-OG) and carbon dioxide. IDH1 and IDH2 are mutated in >70% of lower grade gliomas. Shown to have anti-tumor efficacy in the TS603 glioma cell line and to reduce tumor 2-HG production in HT1080 and U87MG cells. Caused 50-60% growth inhibition over a treatment period of three weeks with no affect in the growth of IDH1 wild-type glioma xenografts in R132H-IDH1 glioma xenografts. Under conditions of near complete 2-HG inhibition, induces demethylation of histone H3K9me3 and expression of genes associated with gliogenic differentiation. Useful chemical probe to assess the biological consequences of IDH1 mutations and the potential of IDH1 inhibition for treating IDH1 mutant tumors. Requires high doses for in vivo activity, but can be used through oral dosing route.

保存温度:

+4°C

运输温度:

Ambient

预期分子量:

462.6

产品形式:

solid

产地:

瑞士

纯度:

>98% (NMR)